The artificial cell design: nanoparticles - Artificial Cells, Cell Engineering and Therapy - page 112

nanoparticles for drug delivery of paclitaxel', Trans. World Biomater. Congr. 1:
199.
Elamanchili P., Diwan M., Cao M. and Samuel J. (2004), `Characterization of poly( D , L -
lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of
antigens to dendritic cells', Vaccine, 22(19): 2406±12.
Feng S.S., Mu L., Win K.Y. and Huang G. (2004), `Nanoparticles of biodegradable
polymers for clinical administration of paclitaxel', Curr. Med. Chem., 11(4): 413±
424.
Gao H., Wang J.Y., Shen X.Z., Deng Y.H. and Zhang W. (2004), `Preparation of
magnetic polybutylcyanoacrylate nanospheres encapsulated with aclacinomycin A
and its effect on gastric tumor', World J. Gastroenterol., 10(14): 2010±2013.
Gianni L., Kearns C.M., Giani A., Capri G., Vigano L., Lacatelli A., Bonadonna G. and
Egorin M.J. (1995), `Nonlinear pharmacokinetics and metabolism of paclitaxel and
its pharmacokinetic/pharmacodynamic relationships in humans', J. Clin. Oncol.,
13: 180±190.
Hamaguchi T., Matsumura Y., Suzuki M., Shimizu K., Goda R., Nakatomi I., Yokoyama
M., Kataoka K. and Kakizoe T. (2005), `NK105, a paclitaxel-incorporating micellar
nanoparticles formulation, can extend in vivo antitumour activity and reduce the
neurotoxicity of paclitaxel', Br. J. Cancer, 92(7): 1240±1246.
Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault P.R.L., Rivera E., Esmaeli
B., Ring S.E., Bedikian A., Hortobagyi G.N. and Ellerhorst A. (2002), `Phase I and
pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized,
nanoparticle formulation of paclitaxel', Clin. Cancer Res., 8: 1038±1044.
Jones M.C. and Leroux J.C. (1999), `Polymeric micelles ± a new generation of colloidal
drug carriers', Eur. J. Pharm. Biopharm., 48: 101±111.
Jordan M.A., Toso R.J., Thrower D. and Wilson L. (1993), `Mechanism of mitotic block
and inhibition of cell proliferation by taxol at low concentrations', Proc. Natl Acad.
Sci. USA, 90: 9552±9556.
Kataoka K., Matsumoto T., Yokoyama M., Okano T., Sakurai Y., Fukushima S.,
Okamoto K. and Kwon G. S. (2000), `Doxorubicin-loaded poly(ethylene glycol)-
poly(-benzyl- L -aspartate) copolymer micelles: their pharmaceutical characteristics
and biological significance', J. Control. Rel. 64: 143±153.
Kaul G. and Amiji M. (2005), `Tumor-targeted gene delivery using ploy (ethylene
glycol)-modified gelatin nanoparticles: in vitro and in vivo studies', Pharm. Res.,
22(6): 951±961.
Kearns C.M., Gianni L. and Egorin M.J. (1995), `Paclitaxel pharmacokinetics and
pharmacodynamics', Semin. Oncol., 22: 16±23.
Kolodgie F.D., John M., Khurana C., Farb A., Wilson P.S., Acampado E., Desai N.,
Soon-Shiong P. and Virmani R. (2002), `Sustained reduction of in-stent neointimal
growth with the use of a novel systemic nanoparticle paclitaxel', Circulation, 106:
1195±1198.
Lboutounne H., Faivre V., Falson F. and Pirot F. (2004), `Characterization of transport of
chlorexidine-loaded nanocapsules through hairless and wistar rat skin', Skin

Pharmacol. Physiol., 17(4): 176±182.
Losa C., Calvo P., Castro E., Vila-Jato L. and Alonso M. (1991), `Improvement of ocular
penetration of amikacin sulphate by association to poly(butylcyanoacrylate)
nanoparticles', J. Pharm. Pharmacol., 43: 548±552.
Miyazaki S., Takahashi A. and Kubo W. (2003), `Poly n-butylcyanoacrylate (PNBCA)
nanocapsules as a carrier for NSAIDs: in vitro release and in vivo skin penetration',
J. Pharm. Pharmaceut. Sci., 6(2): 240±245.